We are analyzing https://link.springer.com/article/10.1007/s11427-017-9176-7.

Title:
The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy | Science China Life Sciences
Description:
Cancer treatment in the past few years has been transformed by a new kind of therapy that targets the immune system instead of the cancer itself to reinvigorate antitumor immunity with astonishing results. However, primary and acquired resistance to this type of treatment, namely immune checkpoint blockade (ICB), continue to counter treatment efficacy. In many cases, resistance has been attributed to defective or chronically enhanced interferon signaling and/or upregulation of alternative immune checkpoints, including T-cell immunoglobulin mucin-3 (Tim-3) and its ligand galactin-9 (Gal-9). In this article, we briefly describe the current knowledge of common checkpoint resistance mechanisms, focusing on the Tim-3/Gal-9 pathway as an alternative checkpoint that holds great promise as another target for ICB.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

pubmed, article, google, scholar, cas, cancer, central, cell, immunol, tim, galectin, immune, cells, nat, immunity, immunotherapy, kuchroo, tcell, resistance, rev, lee, hirashima, tumor, type, blockade, regulates, mucin, yang, hung, checkpoint, interferon, signaling, china, access, freeman, sci, anderson, research, ligand, protein, human, usa, wang, med, zhu, schreiber, chen, university, privacy, cookies,

Topics {✒️}

ifnγ-dependent tissue-immune homeostasis mrl/lpr lupus-prone mice galectin-9-independent ligand-binding surface month download article/chapter suppress t-cell proliferation international research-intensive centers nuclear factor-kappab activation t-cell immunoglobulin mucin-3 mesenchymal stem/stromal cells mien-chie hung cd8 t-cell responses innate immune sensing calcium-calpain-caspase-1 pathway beta-galactoside binding lectin cd8 t-cell exhaustion china life sci regulating anti-tumor immunity china medical university tumor-infiltrating tim-3 virus-specific humoral ifn-γ pathway genes peritumoral immune tolerance full article pdf cd44 reciprocally regulates growing tumors induce t-cell exhaustion tim-3 mediates phagocytosis tim-3 ligand regulates privacy choices/manage cookies therapeutic pd-1 blockade alternative immune checkpoints article yang immune checkpoint blockade immune-checkpoint blockade related subjects chronic viral infection shape tumour immunogenicity encephalitogenic th1/th17 th1-suppressive effects phosphoinositide 3-kinase pathway experimental autoimmune encephalomyelitis interferon receptor promotes galectin-9 induces apoptosis emerging therapeutic targets phosphotyrosine-dependent coupling immune checkpoint target tim-3/gal-9 pathway impaired interferon signaling common immune defect tumor-intrinsic

Questions {❓}

Antigen-independent induction of Tim-3 expression on human T cells by the common?
Galectins and immune responses-just how do they do those things they do?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy
         description:Cancer treatment in the past few years has been transformed by a new kind of therapy that targets the immune system instead of the cancer itself to reinvigorate antitumor immunity with astonishing results. However, primary and acquired resistance to this type of treatment, namely immune checkpoint blockade (ICB), continue to counter treatment efficacy. In many cases, resistance has been attributed to defective or chronically enhanced interferon signaling and/or upregulation of alternative immune checkpoints, including T-cell immunoglobulin mucin-3 (Tim-3) and its ligand galactin-9 (Gal-9). In this article, we briefly describe the current knowledge of common checkpoint resistance mechanisms, focusing on the Tim-3/Gal-9 pathway as an alternative checkpoint that holds great promise as another target for ICB.
         datePublished:2017-10-11T00:00:00Z
         dateModified:2017-10-11T00:00:00Z
         pageStart:1058
         pageEnd:1064
         sameAs:https://doi.org/10.1007/s11427-017-9176-7
         keywords:
            cancer
            Tim-3
            galectin-9
            immune checkpoints
            immunotherapy
            Life Sciences
            general
         image:
         isPartOf:
            name:Science China Life Sciences
            issn:
               1869-1889
               1674-7305
            volumeNumber:60
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Science China Press
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Riyao Yang
               affiliation:
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mien-Chie Hung
               affiliation:
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
                     name:China Medical University
                     address:
                        name:Center for Molecular Medicine and Graduate Institute of Biomedical Sciences, China Medical University, Taichung, China
                        type:PostalAddress
                     type:Organization
                     name:Asia University
                     address:
                        name:Department of Biotechnology, Asia University, Taichung, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy
      description:Cancer treatment in the past few years has been transformed by a new kind of therapy that targets the immune system instead of the cancer itself to reinvigorate antitumor immunity with astonishing results. However, primary and acquired resistance to this type of treatment, namely immune checkpoint blockade (ICB), continue to counter treatment efficacy. In many cases, resistance has been attributed to defective or chronically enhanced interferon signaling and/or upregulation of alternative immune checkpoints, including T-cell immunoglobulin mucin-3 (Tim-3) and its ligand galactin-9 (Gal-9). In this article, we briefly describe the current knowledge of common checkpoint resistance mechanisms, focusing on the Tim-3/Gal-9 pathway as an alternative checkpoint that holds great promise as another target for ICB.
      datePublished:2017-10-11T00:00:00Z
      dateModified:2017-10-11T00:00:00Z
      pageStart:1058
      pageEnd:1064
      sameAs:https://doi.org/10.1007/s11427-017-9176-7
      keywords:
         cancer
         Tim-3
         galectin-9
         immune checkpoints
         immunotherapy
         Life Sciences
         general
      image:
      isPartOf:
         name:Science China Life Sciences
         issn:
            1869-1889
            1674-7305
         volumeNumber:60
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Science China Press
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Riyao Yang
            affiliation:
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mien-Chie Hung
            affiliation:
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
                  name:China Medical University
                  address:
                     name:Center for Molecular Medicine and Graduate Institute of Biomedical Sciences, China Medical University, Taichung, China
                     type:PostalAddress
                  type:Organization
                  name:Asia University
                  address:
                     name:Department of Biotechnology, Asia University, Taichung, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Science China Life Sciences
      issn:
         1869-1889
         1674-7305
      volumeNumber:60
Organization:
      name:Science China Press
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:China Medical University
      address:
         name:Center for Molecular Medicine and Graduate Institute of Biomedical Sciences, China Medical University, Taichung, China
         type:PostalAddress
      name:Asia University
      address:
         name:Department of Biotechnology, Asia University, Taichung, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Riyao Yang
      affiliation:
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:Mien-Chie Hung
      affiliation:
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
            name:China Medical University
            address:
               name:Center for Molecular Medicine and Graduate Institute of Biomedical Sciences, China Medical University, Taichung, China
               type:PostalAddress
            type:Organization
            name:Asia University
            address:
               name:Department of Biotechnology, Asia University, Taichung, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
      name:Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
      name:Center for Molecular Medicine and Graduate Institute of Biomedical Sciences, China Medical University, Taichung, China
      name:Department of Biotechnology, Asia University, Taichung, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(288)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

4.05s.

LINK . SPRINGER . COM {}